StockNews.AI
NVO
StockNews.AI
195 days

Novo Nordisk files annual report with the SEC

1. Novo Nordisk filed its Annual Report 2024 with the SEC. 2. The report includes financial details from the past year. 3. Novo Nordisk's global presence spans 80 countries and 170 markets. 4. Company focuses on innovations in chronic disease treatment. 5. Shareholders may request free audited financial statements.

3m saved
Insight
Article

FAQ

Why Neutral?

Filings typically reflect financial health but lack immediate market impact examples.

How important is it?

Annual reports provide key insights into a company's performance and future expectations.

Why Long Term?

Ongoing financial transparency can influence investor trust over time, as seen with similar firms.

Related Companies

NVOAMGNSNY
Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2024. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial statements free of charge upon request to investor-relations@novonordisk.com. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contact for further information Media: Ambre James-Brown +45 3079 9289abmo@novonordisk.comLiz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.comInvestors: Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.comDavid Heiberg Landsted +45 3077 6915 dhel@novonordisk.comSina Meyer +45 3079 6656 azey@novonordisk.comIda Schaap Melvold +45 3077 5649 idmg@novonordisk.comMax Ung+45 3077 6414mxun@novonordisk.comFrederik Taylor Pitter +1 609 613 0568fptr@novonordisk.com PR250205-SEC-filing

Related News